NCT07083739

A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

Phase II Clinical Trial on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 320 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is an extension of the TQB3473-III-01 study, aimed at evaluating the safety and efficacy of TQB3473 tablets in adult patients with persistent or chronic ITP who have received at least one ITP standard treatment that is ineffective or has recurred after treatment. This is a single arm, open label, multi cohort, multi center Phase II clinical study.

Conditions

• Primary Immune Thrombocytopenia

Interventions

Type	Name	Description
DRUG	TQB3473 Tablets	TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.

Timeline

• Start date: 2025-08-01
• Primary completion: 2027-09-01
• Completion: 2028-03-01
• First posted: 2025-07-24
• Last updated: 2025-07-24

Locations

51 sites across 1 country: China